PERSISTENCE WITH BISPHOSPHONATE THERAPY AND THE IMPACT OF DOSING FREQUENCY IN PATIENTS WITH POST-MENOPAUSAL OSTEOPOROSIS
Author(s)
Penning-van Beest FJA1, Goettsch WG2, Erkens JA2, Herings RMC2, 1 PHARMO Institute, Utrecht, Utrecht, Netherlands; 2 PHARMO Institute, Utrecht, Netherlands
OBJECTIVES: The aim of this study was to compare the persistence of use of daily and weekly administered bisphosphonates. METHODS: Data were obtained from the PHARMO database, which includes linked drug-dispensing records and hospital records of more than one million subjects in defined areas in the Netherlands. New female users of alendronate, etidronate or risedronate aged 55 years and older in the period January, 2000 - September, 2003, were included in the study cohort. One-year persistence of treatment was determined by using episodes of bisphosphonate treatment based on the method of Catalan. The effect of the dosing regimen and other determinants including age, co-medication and fractures, on persistence was assessed. RESULTS: The study cohort included 2124 new users of bisphosphonates. Overall, one-year persistence of bisphosphonates was low; only 911 (43%) users were persistent. Etidronate users were less persistent (30%) than alendronate and risedronate users (46% and 42%, respectively). Among alendronate users, patients on the weekly regimen were more persistent (52%) than those on the daily regimen (35%). A multivariate analysis including age, co-medication and fractures, showed that patients using alendronate weekly were 2.26 times more likely to be persistent (95%CI 1.66 - 3.09) compared to patients using alendronate daily. CONCLUSIONS: Our results indicate that persistence of bisphosphonate use is higher with a less frequent dosing regimen. The improved persistence of the weekly administered alendronate may theoretically be explained by a reduced frequency to experience drug-related acute adverse effects. However, persistence for both regimens can be considered to be suboptimal and leaves room for improvement.
Conference/Value in Health Info
2004-10, ISPOR Europe 2004, Hamburg, Germany
Value in Health, Vol. 7, No. 6 (November/December 2004)
Code
POS8
Topic
Patient-Centered Research
Topic Subcategory
Adherence, Persistence, & Compliance
Disease
Musculoskeletal Disorders